Oor Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
Hoofkantoor251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Gestig2018
StatusAktief
Patente1 patent
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
Resensies
Nog geen resensies nie. Met Assertio Therapeutics, Inc. gewerk? Wees die eerste om jou ervaring te deel.
Regsinligting
| Regsnaam | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20Bekyk op GLEIF ↗ |
| Geregistreerde adres | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| Status | Aktief |
Bronne: GLEIF · bygewerk Okt. 16, 2026
Kontak en skakels
Ligging
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Is dit jou maatskappy?
Eis hierdie bladsy gratis op om jou logo, produkte, foto's en poste by te voeg, en om resensies te beantwoord.
Eis hierdie bladsy opSluit by Heelky aan om te verbind, aan te stel en te groei
Skep 'n gratis rekening om mense boodskappe te stuur, vir poste aansoek te doen en missies te plaas.
Sluit nou aan — dit is gratis